SCHEMBL3243790

SCHEMBL3243790

COc1ccc(Cc2c(F)cccc2F)c(NC(=O)CNS(=O)(=O)c2ccc(OC)c(OC)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 2/20 0.50
KMT2A Q03164 3/20 0.49
F2 P00734 2/20 0.49
ALDH1A1 P00352 7/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPK1 P28482 1/20 0.47
TMPRSS6 Q8IU80 1/20 0.47
LMNA P02545 3/20 0.46
POLB P06746 2/20 0.45
HTT P42858 3/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256160 0.93 MEP1B (0.50) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3256207 0.89 MEP1B (0.48) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3251173 0.87 MEP1B (0.50) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3253072 0.87 MEP1B (0.52) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3254908 0.85 MEP1B (0.50) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3247433 0.85 MEP1B (0.50) MEP1BKMT2AF2ALDH1A1TSHR
SCHEMBL3256517 0.85 ALDH1A1 (0.51) MEP1BKMT2AF2ALDH1A1MAPT
SCHEMBL3254803 0.85 LMNA (0.55) KMT2AALDH1A1MAPTTSHRNPSR1
SCHEMBL3253073 0.83 MEP1B (0.51) MEP1BKMT2AF2ALDH1A1TSHR
SCHEMBL3263747 0.82 MEP1B (0.54) MEP1BKMT2AF2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MEP1B 1627/4885KMT2A 1181/4885F2 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.